教室員
松本 錦之介Matsumoto Kinnosuke M.D.
略歴
2014年 |
金沢大学医学部医学科卒業 |
2014年 |
大阪急性期・総合医療センター 初期臨床研修医 |
2016年 |
大阪急性期・総合医療センター 後期臨床研修医 |
2019年 |
近畿中央呼吸器センター 内科専修医 |
2021年 |
大阪大学医学部附属病院 呼吸器内科 医員 |
2022年 |
大阪大学大学院医学系研究科 呼吸器・免疫内科学 兼 微生物研究所 情報伝達分野 博士課程 |
所属学会
日本内科学会、日本呼吸器学会、日本呼吸器内視鏡学会、日本肺癌学会、日本結核・非結核性抗酸菌症学会
資格等
内科学会認定医、呼吸器学会専門医、がん治療認定医、結核・抗酸菌症認定医、気管支鏡専門医、難病指定医、身体障害者指定医
臨床
呼吸器疾患の中でも肺炎、肺癌、慢性閉塞性肺疾患は非常に罹患率が高く、世界的にみても死因の上位に位置しております。間質性肺疾患を含めて、これらの疾患群は、現代の高齢化社会を反映して、今後も増加が予想されます。われわれ呼吸器内科医にとって、臨床現場で患者さんのニーズに沿った適切な医療を提供することはもとより、呼吸器疾患の病態解明および近年の免疫療法のような創薬なども重要な使命の1つだと考えております。大阪大学では、近畿中央呼吸器センターのような呼吸器専門病院などで重ねた臨床経験を生かし、基礎研究を通して疾患の病態解明に取り組んでいきたいと思っております。
論文
(筆頭著者)
- Matsumoto K, Shiroyama T, Motohiro T, et al. Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study. Cancer Immunol Immunother. 2024;73(1):4.
- Matsumoto K, Tanizaki S (co-first), Tamiya A, et al. Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study. Eur J Clin Pharmacol. 2023;79(4):503-11.
- Matsumoto K, Shiroyama T, Kuge T, et al. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies. Translational Lung Cancer Research. 2022;11(9):1835-46.
- Matsumoto K, Shiroyama T, Yamamoto Y, et al. Impact of the Treatment Line on the Risks and Benefits of Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer and Interstitial Lung Disease. Chest. 2022;162(1):67-69.
- Matsumoto K, Tamiya A, Inagaki Y, et al. Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study. J Geriatr Oncol. 2022;13(2):207-213.
- Matsumoto K, Shiroyama T, Miyake K, et al. Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma. Medicine (Baltimore). 2022;101(1):e28476.
- Matsumoto K, Shiroyama T, Kuge T, et al. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2021;162:175-184.
- Matsumoto K, Shiroyama T, Hashida N, et al. Opposite response of lung adenocarcinoma and its choroidal metastases upon ramucirumab plus docetaxel therapy after immunotherapy: a case report. Angiogenesis. 2021;25(2):147-149.
- Matsumoto K, Tamiya A, Matsuda Y, et al. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res. 2021;10(4):1642-1652.
- Matsumoto K, Nakamura Y, Yuji I, et al. Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: an autopsy case report. Thoracic cancer. 2021;12(7):1137-1140.
- Matsumoto K, Adachi Y, Enomoto T. Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease. Respirology. 2020;25(8):892.
- Matsumoto K, Kobayashi T, Kurahara Y, et al. A case of multi-drug resistant tuberculosis developed after chemotherapy for co-infection of mycobacterium kansasii and mycobacterium tuberculosis. Kekkaku. 2020;95(3):99-102.
- Matsumoto K, Tanizaki S, Yanase T, et al. A case of the synchronous double cancer of the papillary thyroid cancer and the lung adenocarcinoma diagnosed by the endobronchial ultrasound-guided transbronchial needle aspiration. J Jpn Soc Resp Endoscopy. 2019;41:613-618.
(主要共著)
- Nakagawa Y, Matsumoto K, Yamamoto M, et al. A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good's syndrome, and thymoma-associated multi-organ autoimmunity. Respir Med Case Rep. 2022;36:101619.
- Kawachi H, Tamiya M, Matsumoto K, et al. Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. Invest New Drugs. 2022;doi: 10.1007/s10637-022-01214-w.
- Amiya S, Fujimoto J, Matsumoto K, et al. Case report: Acute exacerbation of interstitial pneumonia related to mRNA COVID-19 vaccination. Int J Infect Dis. 2022;116:255-57.
- Enomoto T, Tamiya A, Matsumoto K, et al. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. Clin Transl Oncol. 2021;23(3):582-90.
- Yuichi A, Matsumoto K, Enomoto T. Lung Cancer in Young Patients: The Importance of Assessing Driver Mutations and Treatment Strategies. Lung. 2020;198(2):425-426.
- Shirai Y, Kuno K, Matsumoto K, et al. A case report of anomalous systemic arterial supply to the left basal lung segment from the celiac artery. Ann Jpn Respir Soc. 2018;7(2):119-123.
研究費
2023年 |
イーライリリー IIRグラント |
2023年 |
大阪がん研究助成奨励金 |